Panelists discuss how patient perspectives on new therapies center around clinically meaningful outcomes and survival while balancing individual risk tolerance, with some patients willing to accept ...

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Panelists discuss how chronic neuroinflammation involves distinct mechanisms from acute relapses—including microglial ...

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

The market for artificial sweeteners has been projected to increase by almost 75% from 2025 through 2033, or from $3.11 ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...